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General Methods. All reagents were purchased from commercial suppliers (Aldrich or 
Fisher) and used without further purification. Cyclobis(paraquat-p-phenylene) hexa-
fluorophosphateS1 (CBPQT · 4PF6), 1,5-bis[2-(2-hydroxyethoxy)ethoxy)] naphthaleneS2 
(6a), 1,5-bis[2-(2-(2-hydroxyethoxy)ethoxy)ethoxy]naphthaleneS3 (6b), 1,5-bis[2-(2-(2-(2-
hydroxyethoxy)ethoxy)ethoxy)ethoxy]naphthaleneS3 (6c) and mono-tosylatesS4,S5 of 6a 
(S1) and 6b were prepared according to literature procedures. Preparation and 
characterization of catenanes 1b · 4PF6 and 2b · 4PF6, and their precursors 7b, 8b, and 9b 
was reported in a previous publication.S6 Thin layer chromatography (TLC) was performed 
on silica gel 60 F254 (E. Merck). Column chromatography was performed on silica gel 60F 
(Merck 9385, 0.040–0.063 mm). Melting points were recorded on an Electrothermal 9100 
instrument in open capillary tubes and are uncorrected. Routine nuclear magnetic 
resonance (NMR) spectra were recorded at 25 °C on a Bruker Avance 400 and 500 
spectrometers, with working frequencies of 400 and 500 MHz for 1H, and 100 and 125 
MHz for 13C nuclei respectively. VT-NMR spectra were recorder on a Bruker Avance 500 
spectrometer and temperature-calibrated using neat MeOH (for T < 295 K) and ethylene 
glycol (for T > 295 K). Chemical shifts are reported in ppm relative to the signals 
corresponding to the residual non-deuterated solvents (CDCl3: δ 7.26 ppm, CD3CN: δ 1.93 
ppm, DMF-d7: δ 8.01 ppm). All 13C spectra were recorded with the simultaneous 
decoupling of proton nuclei. Fast atom bombardment mass spectra were obtained on a 
JEOL JMS-600H high resolution mass spectrometer equipped with a FAB probe.  
 
 
Scheme S1. Synthesis of DNP Azide Derivative 7a. 
 
 
A solution of tosylateS4 S1 (1.37 g, 2.78 mmol) and NaN3 (904 mg, 13.9 mmol) in dry 
DMF (15 mL) was heated at 80 °C for 20 h. After cooling, the solvent was removed in 
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vacuo. The resulting brown oil was redissolved in CH2Cl2, and washed first with 1M 
aqueous HCl solution, followed by sat. aqueous NaHCO3 solution. After drying (MgSO4) 
and removal of the solvent, the crude product was subjected to chromatography on silica 
(EtOAc → EtOAc/Me2CO = 50/50) to provide 380 mg of 7a as a viscous yellow oil 
(38%). 7a: MS (FAB+): m/z (rel intensity) = 361 (M+, 100%), 227 (39), 160 (36), 149 (79). 
1H NMR (500 MHz, CDCl3): δ 7.89 (d, 3J (H,H) = 8.2 Hz, 1H), 7.87 (d, 3J (H,H) = 8.2 Hz, 
1H), 7.35 (t, 3J (H,H) = 8.2 Hz, 1H), 7.35 (t, 3J (H,H) = 8.2 Hz, 1H), 6.82 (d, 3J (H,H) = 
8.2 Hz, 1H), 6.80 (d, 3J (H,H) = 8.2 Hz, 1H), 4.28–4.20 (m, 4H), 3.96–3.90 (m, 4H), 3.78–
3.76 (m, 2H), 3.75–3.72 (br m, 2H), 3.68–3.65 (m, 2H), 3.39 (t, 3J (H,H) = 5.0 Hz, 2H), 
2.62 (br s, 1H). 13C NMR (125 MHz, CDCl3): δ 154.16 (2C), 126.65, 126.63, 125.15, 
125.07, 114.60, 114.48, 105.70, 105.68, 72.58, 70.22, 69.69, 69.58, 67.82, 67.76, 61.64, 
50.67. HRMS Calcd for C18H23N3O5: 361.1638. Found: 361.1649. 
 
 
Scheme S2. Synthesis of DNP Monotosylate S2. 
 
 
The diol 6c (1.38 g, 2.69 mmol), NEt3 (555 mg, 780 µL, 5.50 mmol), and DMAP (20 mg, 
0.16 mmol) were dissolved in CH2Cl2 (50 mL). A solution of TsCl (514 mg, 2.71 mmol) in 
CH2Cl2 (18 mL) was added dropwise to this mixture during 12 h at 23 °C (syringe pump, 
1.5 mL/h). After the addition was complete, the reaction mixture was left to stir at 23 °C 
for 4 additional h. It was then washed with sat. aqueous NaHCO3 solution and brine and 
dried (MgSO4). Column chromatography (CH2Cl2 → EtOAc) isolated, in order of elution, 
the ditosylateS3 of 6c (310 mg, 17%), followed by S2 (780 mg, 44%), and unreacted 
starting material (400 mg, 29%). S2: MS (FAB+): m/z (rel intensity) = 666 (M+, 100%). 1H 
NMR (400 MHz, CDCl3): δ 7.75 (d, 3J (H,H) = 8.4 Hz, 1H), 7.74 (d, 3J (H,H) = 8.4 Hz, 
1H), 7.61 (d, 3J (H,H) = 8.0 Hz, 2H), 7.21 (t, 3J (H,H) = 8.4 Hz, 1H), 7.21 (t, 3J (H,H) = 
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8.4 Hz, 1H), 7.12 (d, 3J (H,H) = 8.0 Hz, 2H), 6.68 (d, 3J (H,H) = 8.4 Hz, 1H), 6.68 (d, 3J 
(H,H) = 8.4 Hz, 1H), 4.11–4.07 (m, 4H), 3.97–3.94 (t, 3J (H,H) = 4.4 Hz, 2H), 3.81–3.77 
(m, 4H), 3.62–3.58 (m, 4H), 3.55–3.51 (m, 4H), 3.50–3.46 (m, 8H), 3.41–3.92 (m, 4H), 
3.37–3.35 (m, 2H), 3.13 (br s, 1H), 2.20 (s, 3H). 13C NMR (100 MHz, CDCl3): δ 154.26 
(2C), 144.76, 132.84, 129.80, 127.78, 126.64 (2C), 125.11 (2C), 114.51 (2C), 105.64 (2C), 
72.49, 70.76 (2C), 70.52, 70.49, 70.48, 70.45, 70.38, 70.16, 69.63 (2C), 69.37, 68.46, 
67.83 (2C), 61.43, 21.45. HRMS Calcd for C33H46O12S: 666.2710. Found: 666.2693. 
 
 
 
Scheme S3. Synthesis of DNP Azide Derivative 7c. 
 
 
 
The tosylate S2 (780 mg, 1.17 mmol) and NaN3 (130 mg, 2.00 mmol) were dissolved in 
dry DMF (50 mL). The mixture was stirred at 60 °C for 3 d. After cooling, the solvent was 
removed in vacuo, and the crude material was filtered through a plug of silica, eluting with 
Me2CO. A brown oil was obtained and found to be pure 7c (599 mg, 95%). 7c: MS 
(FAB+): m/z (rel intensity) = 537 (M+, 100%), 510 (28). 1H NMR (400 MHz, CDCl3): δ 
7.79 (br d, 3J (H,H) = 8.4 Hz, 2H), 7.27 (br t, 3J (H,H) = 8.4 Hz, 2H), 6.75 (br d, 3J (H,H) = 
8.4 Hz, 2H), 4.20–4.18 (m, 4H), 3.91–3.88 (m, 4H), 3.73–3.70 (m, 4H), 3.64–3.58 (m, 
8H), 3.56–3.53 (m, 8H), 3.50–3.48 (m, 2H), 3.27–3.24 (m, 2H), 3.09 (br s, 1H). 13C NMR 
(100 MHz, CDCl3): δ 154.30, 154.27, 126.71, 126.70, 125.13, 125.11, 114.60, 114.55, 
105.70, 105.66, 72.54, 70.89, 70.81, 70.66, 70.58, 70.55, 70.50, 70.48, 70.16, 69.91, 69.71 
(2C), 67.86 (2C), 61.47, 50.58. HRMS Calcd for C26H39N3O9: 537.2686. Found: 537.2684. 
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Scheme S4. Synthesis of DNP Azidoalkyne Derivative 8a. 
 
 
Compound 7a (380 mg, 1.05 mmol) was dissolved in dry DMF (30 mL) and treated with 
NaH (60 mg, 2.10 mmol). After the evolution of gas ceased (~30 min), propargyl bromide 
(230 µL of 80% wt solution in PhMe, 2.10 mmol) was added via a syringe. The mixture 
was left to stir at 23 °C for 3 d. Solvent was removed in vacuo and the crude mixture was 
subjected to column chromatography (CH2Cl2/MeOH = 95/5). The first fraction contained 
8a as a brown oil (350 mg, 86%). 8a: 1H NMR (400 MHz, CDCl3): δ 7.88 (d, 3J (H,H) = 
8.4 Hz, 1H), 7.87 (d, 3J (H,H) = 8.4 Hz, 1H), 7.37 (t, 3J (H,H) = 8.4 Hz, 2H), 6.85 (d, 3J 
(H,H) = 8.4 Hz, 1H), 6.85 (d, 3J (H,H) = 8.4 Hz, 1H), 4.29–4.27 (m, 4H), 4.22 (d, 4J (H,H) 
= 2.5 Hz, 2H), 3.99–3.96 (m, 4H), 3.82–3.77 (m, 6H), 3.41 (t, 3J (H,H) = 5.0 Hz, 4H), 2.44 
(t, 4J (H,H) = 2.5 Hz, 1H). 13C NMR (100 MHz, CDCl3): δ 154.35, 154.26, 126.77 (2C), 
125.20, 125.12, 114.77, 114.58,  105.79, 105.75, 79.69, 74.66, 70.77, 70.37, 69.84 (2C), 
69.22, 67.96, 67.94, 58.47, 50.82. 
 
Scheme S5. Synthesis of DNP Azidoalkyne Derivative 8c. 
 
 
Compound 7c (599 mg, 1.12 mmol) was dissolved in dry DMF (25 mL) and treated with 
NaH (48 mg, 2.00 mmol). After the evolution of gas ceased (~30 min), propargyl bromide 
(334 µL of 80% wt solution in PhMe, 3.00 mmol) was added via a syringe. The mixture 
was stirred for 2 d at 23 °C and subsequently quenched with MeOH (2.0 mL). Solvents 
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were removed in vacuo and the resulting crude mixture was filtered through a plug of silica 
(eluting with Me2CO), and subsequently subjected to chromatography (CH2Cl2/Me2CO = 
75/25) to provide pure 8c as the second fraction (300 mg, 47%). 8c: MS (FAB+): m/z (rel 
intensity) = 575 (M+, 94%), 548 (28), 537 (100), 510 (30). 1H NMR (500 MHz, CDCl3): δ 
7.86 (br d, 3J (H,H) = 8.4 Hz, 2H), 7.34 (t, 3J (H,H) = 8.4 Hz, 2H), 6.83 (d, 3J (H,H) = 8.4 
Hz, 2H), 4.29 (t, 3J (H,H) = 5.0 Hz, 4H), 4.18 (d, 4J (H,H) = 2.5 Hz, 2H), 3.99 (t, 3J (H,H) 
= 5.0 Hz, 4H), 3.81–3.77 (m, 4H), 3.71–3.67 (m, 4H), 3.67–3.63 (m, 14H), 3.34 (t, 3J 
(H,H) = 5.0 Hz, 4H), 2.41 (t, 4J (H,H) = 2.5 Hz, 1H). 13C NMR (125 MHz, CDCl3): δ 
154.25 (2C), 126.69 (2C), 124.95 (2C), 114.53 (2C), 105.58 (2C), 79.58, 74.37, 70.90, 
70.88, 70.68, 70.62 (2C), 70.60, 70.54, 70.51, 70.29, 69.89, 69.71 (2C), 69.00, 67.83 (2C), 
58.27, 50.56. HRMS Calcd for C29H41N3O9: 575.2842. Found: 575.2826. 
 
Scheme S6. Synthesis of DNP Diyne Derivative 9a. 
 
 
Diol 6a (1.12 g, 3.33 mmol) was dissolved in dry DMF (25 mL) and treated with NaH 
(192 mg, 8.00 mmol). After the evolution of gas ceased (~30 min), propargyl bromide (2.2 
mL of 80% wt solution in PhMe, 20.0 mmol) was added via a syringe. The mixture was 
stirred at 23 °C for 3 d. MeOH (2.0 mL) was added and the solvents were removed in 
vacuo. Crude brown oil was filtered through a plug of silica, eluting with Me2CO, to 
provide pure 9a (840 mg, 61%) as a dark yellow oil which solidifies on standing, mp 85–
88 °C. 9a: MS (FAB+): m/z (rel intensity) = 412 (M+, 100%), 374 (16). 1H NMR (400 
MHz, CDCl3): δ 7.74 (d, 3J (H,H) = 8.4 Hz, 2H), 7.21 (t, 3J (H,H) = 8.4 Hz, 2H), 6.68 (d, 
3J (H,H) = 8.4 Hz, 2H), 4.11–4.09 (m, 4H), 4.06 (d, 4J (H,H) = 2.4 Hz, 4H), 3.81–3.79 (m, 
4H), 3.65–3.62 (m, 4H), 3.58–3.55 (m, 4H), 2.40 (t, 4J (H,H) = 2.4 Hz, 2H). 13C NMR (100 
MHz, CDCl3): δ 154.21, 126.64, 125.08, 114.53, 105.64, 79.66, 74.80, 70.56, 69.66, 69.06, 
67.80, 58.28. HRMS Calcd for C24H28O6: 412.1886. Found: 412.1875. 
 S7
Scheme S7. Synthesis of DNP Diyne Derivative 9c. 
 
 
Diol 6c (1.28 g, 2.50 mmol) was dissolved in dry DMF (25 mL) and treated with NaH (156 
mg, 6.50 mmol). After the evolution of gas ceased (~30 min), propargyl bromide (1.8 mL 
of 80% wt solution in PhMe, 16.0 mmol) was added via a syringe. The mixture was stirred 
at 23 °C for 3 d. MeOH (2.0 mL) was added and the solvents were removed in vacuo. The 
crude brown oil was filtered through a plug of silica, eluting with Me2CO, to provide pure 
9c (1.39 g, 95%) as a brown oil. 9c: MS (FAB+): m/z (rel intensity) = 588 (M+, 100%), 391 
(33). 1H NMR (500 MHz, CDCl3): δ 7.84 (d, 3J (H,H) = 8.5 Hz, 2H), 7.33 (t, 3J (H,H) = 
8.4 Hz, 2H), 6.83 (d, 3J (H,H) = 8.4 Hz, 2H), 4.29–4.27 (m, 4H), 4.17 (d, 4J (H,H) = 2.4 
Hz, 4H), 4.00–3.95 (m, 4H), 3.80–3.78 (m, 4H), 3.70–3.67 (m, 4H), 3.67–3.63 (m, 16H), 
2.41 (t, 4J (H,H) = 2.4 Hz, 2H). 13C NMR (125 MHz, CDCl3): δ 154.22, 126.65, 124.98, 
114.51, 105.55, 79.56, 74.44, 70.89, 70.60, 70.53, 70.51, 70.29, 69.72, 69.00, 67.81, 58.29. 
HRMS Calcd for C32H44O10: 588.2934. Found: 588.2942. 
 
Scheme S8. Attempted Synthesis of Catenane 1a · 4PF6. 
 
The DNP derivative 8a (9.2 mg, 0.024 mmol), CBPQT · 4PF6 (22.0 mg, 0.02 mmol), and 
CuI (2.0 mg, 0.01 mmol) were dissolved in CD3CN (0.6 mL) and transferred into an NMR 
tube. The purple solution was left at 23 °C for 2 d. After this time, 1H NMR spectroscopy 
and FAB MS showed no sign of formation of 1a · 4PF6. Performing the reaction with a 
CuSO4 · 5H2O / ascorbic acid catalyst mixture gave identical results. 
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Scheme S9. Synthesis of Catenane 1c · 4PF6. 
 
 
The DNP derivative 8c (34.5 mg, 0.06 mmol), CBPQT · 4PF6 (44.0 mg, 0.04 mmol), and 
CuI (11.5 mg, 0.06 mmol) were suspended in CD3CN (0.6 mL) and transferred into an 
NMR tube. The purple solution was allowed to stand at 23 °C for 3 d. After this time, the 
1H NMR spectroscopy showed peaks consistent with the presence of 1c · 4PF6. The 
reaction mixture was filtered through a plug of silica (gradient elution: Me2CO → 2% 
solution of NH4PF6 in Me2CO). Purple fractions were collected, concentrated to a 
minimum volume and the crude catenane 1c · 4PF6 was precipitated by the addition of 
H2O. After filtration and drying, this crude material was analyzed and showed to contain 
CBPQT · 4PF6 and the desired [2]catenane 1c · 4PF6. The crude mixture was dissolved in 
minimum amount of Me2CO and hexane was added dropwise until precipitation of 
CBPQT · 4PF6 occurred. Removal of the solvent from the supernatant provided pure 1c · 
4PF6 (15 mg, 23%) as a purple solid, mp 199–201 °C with decomp. 1c · 4PF6: MS (ESI): 
m/z (rel intensity) = 1530 ([1c · 3PF6]+, 8%), 692 ([1c · 2PF6]2+, 100), 413 ([1c · PF6]3+, 
45). 1H NMR (500 MHz, DMF-d7, 270 K): δ 9.73 (br d, 1H, α-CBPQT4+-H), 9.48 (d, 3J 
(H,H) = 6.5 Hz, 1H, α-CBPQT4+-H), 9.46 (d, 3J (H,H) = 6.6 Hz, 1H, α-CBPQT4+-H), 9.44-
9.34 (br m, 2H, α-CBPQT4+-H), 9.32 (d, 3J (H,H) = 6.8 Hz, 1H, α-CBPQT4+-H), 9.28 (d, 3J 
(H,H) = 6.7 Hz, 1H, α-CBPQT4+-H), 8.81 (br s, 1H, α-CBPQT4+-H), 8.31–8.09 (m, 8H, β-
CBPQT4+-H), 7.85 (br m, 2H, aryl-CBPQT4+-H), 7.82 (br s, 2H, aryl-CBPQT4+-H), 7.72 
(br s, 2H, aryl-CBPQT4+-H), 7.62 (br s, 2H, aryl-CBPQT4+-H), 7.46 (s, 1H, triazole-H), 
6.29 (d, 3J (H,H) = 7.9 Hz, 1H, DNP aryl-H o-O), 6.10–5.91 (m, 11H, DNP aryl-H o-O, 
DNP aryl-H m-O, and CBPQT4+ benzyl-H), 4.18–2.69 (m, 32H), 3.03 (s, 2H, propargyl-
H), 2.54 (d, 3J (H,H) = 7.7 Hz, 1H, DNP aryl-H p-O), 2.53 (d, 3J (H,H) = 8.0 Hz, 1H, DNP 
 S9
aryl-H p-O). HRMS Calcd for C65H73N7O9P2F12 ([1c · 2PF6]2+): 692.7389. Found: 
692.7350. 
 
Scheme S10. Attempted Synthesis of Catenane 2a · 4PF6. 
 
 
 
The DNP derivative 9a (50.0 mg, 0.12 mmol), CBPQT · 4PF6 (44.0 mg, 0.04 mmol), and 
Cu(OAc)2 · H2O (40.0 mg, 0.20 mmol) were dissolved in MeCN (30 mL). The deeply 
bluish-purple solution was stirred at 23 °C for 2 d. The solvent was removed in vacuo, and 
the crude purple solid was subjected to column chromatography on silica (Me2CO → 2% 
solution of NH4PF6 in Me2CO). Several fractions were collected, concentrated to a small 
volume, and precipitated by addition of cold H2O. None of the materials isolated by 
filtration contained any evidence for the presence of 2a · 4PF6 (by 1H NMR spectroscopy 
and FAB MS). Additionally, although 2a · 4PF6 was expected to be purple, all of the 
collected fractions were either colorless or pale yellow. 
 
Scheme S11. Improved Synthesis of Catenane 2b · 4PF6. 
 
 
The DNP derivative 9b (60.0 mg, 0.12 mmol), CBPQT · 4PF6 (44.0 mg, 0.04 mmol), and 
Cu(OAc)2 · H2O (40.0 mg, 0.20 mmol) were dissolved in MeCN (30 mL). The deeply 
bluish-purple solution was stirred at 23 °C for 2 d. The solvent was removed in vacuo, and 
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the crude purple solid was subjected to column chromatography on silica (Me2CO → 2% 
solution of NH4PF6 in Me2CO). Purple fractions were collected and reduced to minimal 
volume. Cold H2O was added to precipitate the purple solid. After filtration and drying, 58 
mg (97%) of 2b · 4PF6 was obtained. The spectroscopic data for this sample were identical 
to one previously reported.S6 The amount of 2b · 4PF6  prepared allowed the collection of 
13C NMR spectrum. 2b · 4PF6: 13C NMR (125 MHz, CD3CN): δ 151.00, 145.12, 144.37, 
136.48, 131.29, 131.07, 128.02, 125.92, 124.45, 124.35, 108.27, 104.12, 70.75, 70.54, 
70.12, 69.70, 69.48, 68.25, 67.84, 57.89. 
 
Scheme S12. Synthesis of Catenane 2c · 4PF6. 
 
 
The DNP derivative 9c (72.0 mg, 0.12 mmol), CBPQT · 4PF6 (44.0 mg, 0.04 mmol), and 
Cu(OAc)2 · H2O (40.0 mg, 0.20 mmol) were dissolved in MeCN (30 mL). The deeply 
bluish-purple solution was stirred at 23 °C for 2 d. The solvent was removed in vacuo, and 
the crude purple solid was subjected to column chromatography on silica (Me2CO → 1% 
solution of NH4PF6 in Me2CO). Purple fractions were collected and concentrated to 
dryness. Cold H2O was added to precipitate the purple solid. After filtration and drying, 
this crude material was analyzed and showed to contain CBPQT · 4PF6 and the desired 2c 
· 4PF6. The crude mixture was dissolved in minimal amount of acetone and hexane was 
added dropwise until precipitation of CBPQT · 4PF6 occurred. Removal of the solvent 
from the supernatant provided pure 2c · 4PF6 (35 mg, 52%) as a purple solid, mp >230 °C 
without decomp. 2c · 4PF6: MS (ESI): m/z (rel intensity) = 1541 ([2c · 3PF6]+, 1%), 698 
([2c · 2PF6]2+, 62), 563 (100), 417 ([2c · PF6]3+, 31). 1H NMR (500 MHz, CD3CN): δ 9.01 
(br s, 2H, α-CBPQT4+-H), 8.86 (br s, 4H, α-CBPQT4+-H), 8.65 (br s, 2H, α-CBPQT4+-H), 
8.02 (br s, 8H, β-CBPQT4+-H), 7.34 (br s, 8H, aryl-CBPQT4+-H), 6.27 (d, 3J (H,H) = 7.8 
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Hz, 2H, DNP aryl-H o-O), 6.02 (t, 3J (H,H) = 8.0 Hz, 2H, DNP aryl-H m-O), 5.74 (br s, 
8H, CBPQT4+ benzyl H), 4.31 (m, 4H), 4.17 (m, 4H), 4.02 (m, 4H), 3.89 (m, 4H), 3.85 (s, 
4H, propargyl-H), 3.73 (m, 2H), 3.56 (m, 2H), 3.40 (m, 2H), 3.19 (m, 2H), 2.50 (br s, 2H, 
DNP aryl-H p-O). HRMS Calcd for C68H74N4O10P2F12 ([6 · 2PF6]2+): 698.2350. Found: 
698.2326. 
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X-Ray Diffraction: Data Collection and Refinement Parameters 
 
 
[9a ⊂ CBPQT] · 4PF6: C60H60F24N4O6P4, crystal size 0.20 × 0.20 × 0.15 mm3, space group 
P1, scan range 8.0 < 2θ < 56.6°, T = 100(2) K, a = 10.163(3), b = 12.669(4), c = 
14.245(5) Å, α  =  99.963(4), β  =  107.120(3), γ  =  112.522(3), V = 1531.9(9) Å3, Z = 1, 
ρcalcd = 1.640 gcm–3, µ(MoKα) = 0.253 mm–1, 7331 unique reflections, of which 5083 were 
taken as observed [I>2σ(I)], R(F) = 0.059, wR(F2) = 0.155 (all data). 
 
1b · 4PF6: C73H83F24N13O7P4, crystal size 0.60 × 0.40 × 0.05 mm3, space group P1, scan 
range 7.8 < 2θ < 53.1°, T = 100(2) K, a = 15.304(7), b = 15.316(7), c = 21.776(14) Å, α  
=  95.059(7), β  =  106.489(7), γ  =  116.953(5), V = 4220(4) Å3, Z = 2, ρcalcd = 1.444 
gcm–3, µ(MoKα) = 0.201 mm–1, 17307 unique reflections, of which 7251 were taken as 
observed [I>2σ(I)], R(F) = 0.076, wR(F2) = 0.239 (all data). 
 
2b · 4PF6: C76H84F24N10O8P4, crystal size 0.50 × 0.40 × 0.20 mm3, space group P1, scan 
range 8.4 < 2θ < 59.7°, T = 100(2) K, a = 13.690(2), b = 13.848(2), c = 24.046(4) Å, α  =  
84.815(2), β  =  85.732(2), γ  =  67.626(2), V = 4194.3(11) Å3, Z = 1, ρcalcd = 1.461 gcm–3, 
µ(MoKα) = 0.203 mm–1, 23132 unique reflections, of which 17155 were taken as observed 
[I>2σ(I)], R(F) = 0.076, wR(F2) = 0.222 (all data).  
 
2c · 4PF6: C80H92F24N13O10P4, crystal size 0.60 × 0.30 × 0.10 mm3, space group P1, scan 
range 7.8 < 2θ < 56.5°, T = 100(2) K, a = 14.021(3), b = 14.121(3), c = 22.210(5) Å, α = 
94.628(2), β = 93.400(2), γ = 93.554(3), V = 4365.5(17) Å3, Z = 2, ρcalcd = 1.470 gcm–3, 
µ(MoKα) = 0.200 mm–1, 20861 unique reflections, of which 13530 were taken as observed 
[I>2σ(I)], R(F) = 0.085, wR(F2) = 0.275 (all data).  
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Supramolecular Organization of Crystallographically Characterized Materials 
 
 
 
Figure S1. Unit cell contents of [2]pseudorotaxane [9a ⊂ CBPQT]4+. Donor rings shown 
in red, acceptor rings in blue, PF6– counterions in gray. Aside from the remaining PF6– 
counterions, hydrogen atoms and solvent molecules were omitted for clarity.  
 
 
 
 
Figure S2. Section of the packing diagram of [2]pseudorotaxane [9a ⊂ CBPQT]4+, viewed 
down the crystallographic a axis. Donor rings shown in red, acceptor rings in blue. Aside 
from PF6– counterions, hydrogen atoms and solvent molecules were omitted for clarity. 
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Figure S3. Unit cell contents of [2]catenane 1b4+. Donor rings shown in red, acceptor rings 
in blue, bridging PF6– counterions in gray. Aside from the remaining PF6– counterions, 
hydrogen atoms and solvent molecules were omitted for clarity.  
 
 
 
 
Figure S4. Section of the packing diagram of [2]catenane 1b4+. Donor rings shown in red, 
acceptor rings in blue. Aside from PF6– counterions, hydrogen atoms and solvent 
molecules were omitted for clarity. 
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Figure S5. Unit cell contents of [2]catenane 2b4+. Donor rings shown in red, acceptor rings 
in blue. Aside from PF6– counterions, hydrogen atoms and solvent molecules were omitted 
for clarity. 
 
 
 
Figure S6. Section of the packing diagram of [2]catenane 2b4+. Donor rings shown in red, 
acceptor rings in blue. Aside from PF6– counterions, hydrogen atoms and solvent 
molecules were omitted for clarity. 
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Figure S7. Unit cell contents of [2]catenane 2c4+. Donor rings shown in red, acceptor rings 
in blue. Aside from PF6– counterions, hydrogen atoms and solvent molecules were omitted 
for clarity. 
 
 
 
Figure S8. Section of the packing diagram of [2]catenane 2c4+. Donor rings shown in red, 
acceptor rings in blue. Aside from PF6– counterions, hydrogen atoms and solvent 
molecules were omitted for clarity. 
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Partial VT-NMR spectra of [2]catenanes 1b,c · 4PF6 and 2b,c · 4PF6 
 
 
 
 
Figure S9. VT-NMR spectra of 1b · 4PF6 (DMF-d7). 
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Figure S10. VT-NMR spectra of 1c · 4PF6 (DMF-d7). 
 S19
 
 
 
 
 
 
Figure S11. VT-NMR spectra of 2b · 4PF6 (DMF-d7). 
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Figure S12. VT-NMR spectra of 2c · 4PF6 (DMF-d7). 
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